Effects of computer-assisted oral anticoagulant therapy

Thrombosis Journal

Volumn 10, Issue , 2012, Pages

  Rasmussen, Rune S ^a,c   Corell, Pernille ^a   Madsen, Poul ^b   Overgaard, Karsten ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b FREDERIKSBERG HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; COMPUTER ASSISTED DRUG THERAPY; FEMALE; HUMAN; INTERMETHOD COMPARISON; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; TIME; TREATMENT DURATION;

EID: 84865485107     PISSN: None     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/1477-9560-10-17     Document Type: Article

References (26)

1. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999, 131(7):492-501.
2. Danish Society of Cardiology report: Trombokardiologi. 2007, http://cardio.synkron.com/graphics/toimport/cardio/user_graphics/Dokumenter/rapporter_pdf/trombokard%202007.pdf.
3. Danish Medicines Agency Prevalence of VKA users in Denmark 2004, Danish Medicines Agency, Copenhagen, Danish Medicines Agency.
4. Lassen JF. Oral anticoagulation treatments - quality assurance 1996, Ph.D.-thesis at the University of Odense and the Clinical Biochemical Department at Vejle Hospital, Denmark, 3446731, 23015806.
5. Gorter JW. Major bleeding during anticoagulation after cerebral ischemia. Neurology 1999, 53:1319-1327. 10.1212/WNL.53.6.1319, 10522891.
6. Nielsen JD, Husted SE, Lassen JF, Nielsen HK, Hansen KF, Antonsen S, Jespersen J. Antikoagulansbehandling. Ugeskr laeger 2000, 162:1247-1252.
7. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994, 120(11):897-902.
8. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996, 335(8):540-546. 10.1056/NEJM199608223350802, 8678931.
9. Steffensen FH, Kristensen K, Ejlersen E, Dahlerup JF, Sørensen HT. Major haemorrhagic complications during oral anticoagulant therapy in a Danish population-based cohort. J Int Med 1997, 242:497-503.
10. Oake N, Jennings A, Forster AJ, Fergusson D, Doucette S, van Walraven C. Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis. CMAJ 2008, 179(3):235-244. 10.1503/cmaj.080171, 2474869, 18663203.
11. Gaughan GL, Dolan C, Wilk-Rivard E, Geary G, Libbey R, Gilman MA, Lanata H. Improving management of atrial fibrillation and anticoagulation in a community hospital. Jt Comm J Qual Improv 2000, 26:18-28.
12. Poller L, Shiach CR, MacCallum PK, Johansen AM, Münster AM, Magalhães A, Jespersen J. Multicentre randomised study of computerised anticoagulant dosage. Lancet 1998, 352:1505-1509. 10.1016/S0140-6736(98)04147-6, 9820298.
13. Vadher B, Patterson DL, Leaning M. Evaluation of a decision support system for initiation and control of oral anticoagulation in a randomised trial. BMJ 1997, 314(7089):1252-1256. 10.1136/bmj.314.7089.1252, 2126598, 9154031.
14. Levi M, de Peuter OR, Kamphuisen PW. Management strategies for optimal control of anticoagulation in patients with atrial fibrillation. Semin Thromb Hemost 2009, 35(6):560-567. 10.1055/s-0029-1240016, 19787560.
15. Gouin-Thibault I, Levy C, Pautas E, Cambus JP, Drouet L, Mahé I, Bal Dit Sollier C, Horellou MH, Golmard JL, Siguret V. Improving anticoagulation control in hospitalized elderly patients on warfarin. J Am Geriatr Soc 2010, 58(2):242-247. 10.1111/j.1532-5415.2009.02675.x, 20374400.
16. Christensen TD, Andersen NT, Attermann J, Hjortdal VE, Maegaard M, Hasenkam JM. Mechanical heart valve patients can manage oral anticoagulant therapy themselves. Eur J Cardiothorac Surg 2003, 23:292-298. 10.1016/s1010-7940(02)00817-5, 12614796.
17. Pink J, Lane S, Pirmohamed M, Hughes DA. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. BMJ 2011, 343:d6333. 10.1136/bmj.d6333, 3204867, 22042753.
18. Britt RP, James AH, Raskino CL, Thompson SG. Factors affecting the precision of warfarin treatment. J Clin Pathol 1992, 45:1003-1006. 10.1136/jcp.45.11.1003, 495033, 1452773.
19. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993, 69:236-239.
20. Christensen TD. Self-management of oral anticoagulant therapy: a review. J Thromb Thrombolysis. 2004, 18:127-143. 10.1007/s11239-004-0209-5, 15789179.
21. Horne BD, Lenzini PA, Wadelius M, Jorgensen AL, Kimmel SE, Ridker PM, Eriksson N, Anderson JL, Pirmohamed M, Limdi NA, et al. Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. Thromb Haemost 2012, 107(2):232-240. 3292349, 22186998.
22. Christensen H, Lauterlein JJ, Sørensen PD, Petersen ER, Madsen JS, Brandslund I. Home management of oral anticoagulation via telemedicine versus conventional hospital-based treatment. Telemed J E Health 2011, 17(3):169-176. 10.1089/tmj.2010.0128, 3079164, 21254841.
23. Olsen TS, Rasmussen BH, Kammersgaard LP, Germer U. Frequency of strokes attributable to underuse of warfarin and platelet inhibitors. Cerebrovasc Dis 2004, 17(suppl 5):1-125.
24. Man-Son-Hing M, Laupacis A. Anticoagulant-related bleeding in older persons with atrial fibrillation. Arch Intern Med 2003, 163:1580-1586. 10.1001/archinte.163.13.1580, 12860581.
25. Shiach CR, Campbell B, Poller L, Keown M, Chauhan N. Reliability of point-of-care prothrombin time testing in a community clinic: a randomised crossover comparison with hospital laboratory testing. Br J Haematol 2002, 119:370-375. 10.1046/j.1365-2141.2002.03888.x, 12406071.
26. Fitzmaurice DA, Machin SJ, . British Society of Haematology Task Force for Haemostasis and Thrombosis Recommendations for patients undertaking self management of oral anticoagulation. BMJ 2001, 323:985-989. 10.1136/bmj.323.7319.985, 1121512, 11679391, British Society of Haematology Task Force for Haemostasis and Thrombosis.